文献速递银屑病与炎症性皮肤病

靶向免疫调节剂治疗中重度斑块状银屑病的比较有效性:系统综述与网络Meta分析

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
PubMed 文献 · J Am Acad Dermatol · 2018-02-10

本文系统综述了8种靶向免疫调节剂治疗成人中重度斑块状银屑病的随机对照试验,主要结局为银屑病面积与严重度指数改善75%。网络Meta分析显示,依奇珠单抗、布罗达鲁单抗和英夫利西单抗在达到PASI 75方面均显著优于乌司奴单抗、阿达木单抗、依那西普和阿普司特。

要点

  • 网络Meta分析中,各药达到PASI 75的相对风险由低到高为阿普司特6.2、依那西普9.6、阿达木单抗13.0、乌司奴单抗14.0、司库奇尤单抗15.4、英夫利西单抗16.2、布罗达鲁单抗17.3、依奇珠单抗17.9。
  • 依奇珠单抗、布罗达鲁单抗和英夫利西单抗在达到PASI 75方面均显著优于乌司奴单抗、阿达木单抗、依那西普和阿普司特。
  • 白细胞介素17A抑制剂在达到皮损清除方面比乌司奴单抗更有效,且总体上比依那西普、阿达木单抗和阿普司特更有效。

核心结论

  • 白细胞介素17A抑制剂在达到皮损清除方面比乌司奴单抗更有效,且总体上比依那西普、阿达木单抗和阿普司特更有效。

研究设计与样本

  • 系统综述与网络Meta分析,纳入8种靶向免疫调节剂的安慰剂对照和头对头随机试验,评估临床获益或危害。
  • 主要结局为银屑病面积与严重度指数改善75%。
  • 网络Meta分析经安慰剂反应调整后对药物间进行间接比较。

主要发现

  • 网络Meta分析中,各药达到PASI 75的相对风险由低到高为阿普司特6.2、依那西普9.6、阿达木单抗13.0、乌司奴单抗14.0、司库奇尤单抗15.4、英夫利西单抗16.2、布罗达鲁单抗17.3、依奇珠单抗17.9。
  • 依奇珠单抗、布罗达鲁单抗和英夫利西单抗在达到PASI 75方面均显著优于乌司奴单抗、阿达木单抗、依那西普和阿普司特。
  • 在有头对头研究数据的情况下,结果与头对头研究相似。

关键数值与推荐

  • 网络Meta分析中,各药达到PASI 75的相对风险由低到高为阿普司特6.2、依那西普9.6、阿达木单抗13.0、乌司奴单抗14.0、司库奇尤单抗15.4、英夫利西单抗16.2、布罗达鲁单抗17.3、依奇珠单抗17.9。
  • 依奇珠单抗、布罗达鲁单抗和英夫利西单抗在达到PASI 75方面均显著优于乌司奴单抗、阿达木单抗、依那西普和阿普司特。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 大部分证据为短期(覆盖10-16周)。
  • 直接比较有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The comparative effectiveness of available targeted immunomodulators for moderate-to-severe psoriasis has not been evaluated. OBJECTIVE: To evaluate the comparative effectiveness of targeted immunomodulators for adults with moderate-to-severe plaque psoriasis. METHODS: Systematic literature review of placebo-controlled and head-to-head randomized trials of 8 targeted immunomodulators that evaluated clinical benefits or harm. The primary outcome was a 75% improvement on the Psoriasis Area and Severity Index. We also conducted a network meta-analysis adjusted for placebo response to perform indirect comparisons between agents. RESULTS: In the network meta-analysis, the targeted immunomodulators ordered by increasing relative risk (demonstrating greater likelihood) of achieving a 75% improvement on the Psoriasis Area and Severity Index relative to placebo were as follows: apremilast (6.2), etanercept (9.6), adalimumab (13.0), ustekinumab (14.0), secukinumab (15.4), infliximab (16.2), brodalumab (17.3), and ixekizumab (17.9). Ixekizumab, brodalumab, and infliximab were all statistically superior to ustekinumab, adalimumab, etanercept, and apremilast; results were similar to those of head-to-head studies where data were available. LIMITATIONS: Much of the evidence is short-term (covering 10-16 weeks); limited direct comparisons. CONCLUSIONS: The interleukin 17A inhibitors are more effective in achieving clearance than ustekinumab, and they are generally more effective than etanercept, adalimumab, and apremilast.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Loos AM, Liu S, Segel C, et al. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. J Am Acad Dermatol. 2018. PMID: 29438757. doi:10.1016/j.jaad.2018.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。